Psoriatic arthritis

Dr. John Cush RheumNow
1 year ago
EULAR 2024: Tuesday’s Topic Panel (PSA) with RheumNow https://t.co/j4I1bC9ROD
I am a big fan of animals and wildlife. Whenever I can, I try to wander outdoors to look for our friends big and small in the animal kingdom. If it rains, as often it does in the UK, the latest edition of Planet Earth will do. So, I was naturally attracted to the presentation by Professor Iain McInnes from the University of Glasgow, oral presentation OP0195 at #EULAR2024 where the link between camels and psoriatic arthritis was made.

Dr. John Cush RheumNow
1 year ago
Can we prevent psoriatic arthritis?
PsA affects up to 30% of PsO patients. Understanding factors that lead to PsA helps in early interventions. Most PsA patients have preceding PsO.
https://t.co/03H4YrvxMe https://t.co/efUVaccSHn


Mrinalini Dey DrMiniDey
1 year ago
Is Izokibep the new kid on the block in PsA?
➡️ IL-17A inhibitor
➡️ Complete resolution of enthesitis at 16w
➡️ Overall good safety data
LBA0005 #EULAR2024 @RheumNow https://t.co/8htPOz9YCG


Peter Nash drpnash
1 year ago
RISK OF NON-MELANOMA SKIN CANCER WITH TNFi AND OTHER bDMARDs IN PATIENTS WITH PSORIATIC ARTHRITIS: A SWEDISH AND DANISH COHORT STUDY- despite having minimal sun 25% increase NMSC TNFis vs other bDMARDs - skin checks ! @RheumNow #EULAR2024

Peter Nash drpnash
1 year ago
EULAR Abstract Archive
POS0894 (2024)
SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
Reassuring 15000 pt yrs f/u RA PsA AS https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

Peter Nash drpnash
1 year ago
EULAR Abstract Archive
RISK OF PsA IN PATIENTS WITH PsO UNDERGOING bDMARDs GLOBAL POPULATION STUDY (TRINETX)
870,000 PsO pts without PsA treated with bDMARDS - Il12/23i and Il23i. 30-37% lower PsA developed than comparators https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

Peter Nash drpnash
1 year ago
EULAR Abstract Archive
OP0031 (2024)
COMPARATIVE ANALYSIS OF TNF INHIBITORS & IL17 INHIBITORS IN PSORIATIC ARTHRITIS: CARDIOVASCULAR OUTCOMES signif absolute risk diff 3 % ischaemic heart disease 2 % heart failure TNFi vs IL17i https://t.co/fNIiMt4caL. @RheumNow #EULAR2024

Peter Nash drpnash
1 year ago
Grappa « difficult to treat and complex to manage» PsA meeting - SLR, Patient & rheumo survey, working on definition eg - fail 1 csDMARD & 2 bDMARDs different MOA @RheumNow #EULAR2024

Aurelie Najm AurelieRheumo
1 year ago
PRO-SPIRIT 1100+ PsA Observational study
IXE i= TNFi and JAKi for improving joint dis activity in IXE higher previous b/tsDMARD & less concomitant csDMARDs
IXE & IL-17Ai = faster improvement cDAPSA than IL-12/23i or IL-23i
Abst LBA0002 #EULAR2024 @RheumNow https://t.co/8DbtCQECNN
